

**Organisation Strategy for
 Denmark's engagement with
 International AIDS Vaccine Initiative (IAVI)
 2014-2018**



The work of IAVI

IAVI is a non-profit product development partnership (PDP) with a mission to ensure the development of an effective preventive AIDS vaccine with a special focus on the HIV virus strains prevalent in developing countries.

PDPs are non-profit product development partnerships which generate resources and forge partnerships across public, private and philanthropic sectors to accelerate development of new health technologies.

Denmark supports IAVI because

- An AIDS vaccine is needed in order to effectively end the AIDS pandemic. Industry research into an AIDS vaccine is limited due to perceived uncertain return on investment compared to research and development cost.
- It is in line with Denmark's strategic ambition of being at the forefront of the response to HIV and AIDS.

Key challenges for IAVI

- Attracting sufficient funding as research requires long-term funding and outcomes are not certain.
- An ever mutating HIV virus.

Denmark will expect IAVI to


- Maintain a clinical pipeline of AIDS vaccines relevant for parts of the world with the highest burden of HIV, thereby increasing the likelihood of a vaccine.
- Strengthen research capacity in developing countries including South-driven research.

Denmark will follow-up by

- Monitoring Danish priority areas based on IAVI's own framework.
- Participating in annual donor consultations and close dialogue.

IAVI	
Established	1996
HQ	New York, NY, USA
Regional offices	Amsterdam, The Netherlands; Nairobi, Kenya; Johannesburg, South Africa; and New Delhi, India
Human resources	155
CEO	Margaret G. McGlynn
Financial resources	66.6 mill. USD (2013)
Denmark's contribution	5 mill. DKK annually

Donors (2014 projections)



BMGF: Bill & Melinda Gates Foundation
 US NIH: National Institutes of Health